News

Update on CALAVI phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19.- AstraZeneca

Read time: 1 mins

Published:13th Nov 2020

The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the trials. The CALAVI programme comprised two Phase II trials investigating acalabrutinib plus BSC versus BSC alone in hospitalised patients with COVID-19 disease. The safety and tolerability profiles for Calquence in the CALAVI Phase II trials were consistent with previous trials. The data will be presented in due course. Results from the CALAVI Phase II trials do not impact approved indications or pending approvals for Calquence in patients with blood cancers.

Condition: Coronavirus/COVID-19 Infection

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 mins

Drug news

FDA issues emergency use authorisation of Pemgarda (pemivibart) (formerly VYD 222) for pre-exposure prophylaxis of COVID 19,- Invivyd Inc.

Invivyd, Inc. a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that Pemgarda (pemivibart), formerly VYD 222, a half-life extended monoclonal antibody (mAb), has received emergency use authorization (EUA) from the FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.

3 min

Drug news

New data from three real-world retrospective studies of Veklury (remdesivir) are presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

2 min

See all news